← 返回

基于机器学习的评分系统通过量化结直肠癌中与微卫星高度不稳定肿瘤的相似性识别高免疫活性微卫星稳定肿瘤:开发与定量研究

英文原题:A Machine Learning-Based Scoring System to Identify High Immunoactivity Microsatellite Stability Tumors by Quantifying Similarity to Microsatellite Instability-High Tumors in Colorectal Cancers: Development and Quantitative Study.

查看英文原题

A Machine Learning-Based Scoring System to Identify High Immunoactivity Microsatellite Stability Tumors by Quantifying Similarity to Microsatellite Instability-High Tumors in Colorectal Cancers: Development and Quantitative Study.

PubMed 2025/10/16(内容时间) JMIR Form Res Q2 · IF 2.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

与 MSI-H 结直肠癌患者相比,部分 MSS 结直肠癌患者呈现出相似的高免疫活性免疫细胞分布。

中文摘要

与微卫星高度不稳定(MSI-H)结直肠癌(CRC)相比,微卫星稳定(MSS)CRC对免疫检查点抑制剂(ICI)的应答有限。不过,既往研究显示部分MSS CRC对ICI敏感,但目前仍缺乏明确的治疗判定标准。

本研究旨在分析MSSTIL(肿瘤浸润淋巴细胞)的特征,并基于多种因素开发一种新型计算工具,用于预测CRC患者MSS与MSI-H状态之间的相似性。

研究者收集并分析188例CRC患者的微卫星状态、免疫细胞分布、临床特征和基因突变数据,并采用统计学方法及Cox回归分析。研究团队利用堆叠式极端梯度提升分类器开发集成机器学习MSI-H评分,根据免疫细胞分布、临床特征和基因突变量化患者数据与MSI-H数据的相似性。该模型稳健,并能处理免疫细胞分布及基因突变输入数据缺失的情况。

该评分器表现良好(10个随机种子的平均Cohen系数为0.40,标准差0.05),能够识别TIL分布与真实MSI-H CRC相似的MSI-H样MSS样本。MSI-H样MSS CRC与MSI-H CRC的TIL特征未见显著差异。MSI-H样MSS CRC与MSS CRC之间的差别可能体现在肿瘤基质区的调节性T细胞(P=0.09)和巨噬细胞(P=0.16)群体。

部分MSS CRC患者具有与MSI-H CRC患者相似的免疫细胞分布和较高的免疫活性。MSI-H评分可量化MSS CRC与MSI-H CRC的相似程度,为更个体化、有效的癌症免疫治疗提供了有前景的方向,并为MSS CRC潜在ICI治疗靶点提供临床参考。

展开英文摘要原文

Microsatellite stability (MSS) colorectal cancers (CRCs) have a limited response to immune checkpoint inhibitors (ICIs) compared to microsatellite instability-high (MSI-H) CRCs. Nevertheless, previous studies have shown that some MSS CRCs are sensitive to ICIs, although established criteria for treatment justification are still lacking.

This study aimed to test the tumor-infiltrating lymphocyte (TIL) features of MSS and develop a novel computational tool for the similarity prediction between MSS and MSI-H status in patients with CRC based on multiple factors.

We collected and analyzed data from 188 patients with CRC, including MSI status, immune cell distributions, clinical features, and gene mutations, using statistical methods and Cox regression. An ensemble machine learning-based MSI-H score was developed using stacked extreme gradient boosting classifiers to quantify the similarity of patient data to MSI-H data based on immune cell distributions, clinical features, and gene mutations. The model was robust and could address missing input data for immune cell distributions and gene mutations.

The scorer performed well (mean Cohen of 0.40, SD 0.05, over 10 random seeds) in identifying MSI-H-like MSS samples with TIL distributions similar to genuine MSI-H CRCs. No significant difference was observed between the TIL features of MSI-H-like MSS CRCs and MSI-H CRCs. The disparity between MSI-H-like MSS CRCs and MSS CRCs potentially lies in the T regulatory cells (P=.09) and macrophage (P=.16) populations within the tumor stromal region.

Some patients with MSS CRC presented similar immune cell distributions with high immunoactivity compared to patients with MSI-H CRC. The MSI-H score serves as a metric to quantify the similarity of MSS CRCs to MSI-H CRCs and presents a promising avenue for more personalized and effective cancer immunotherapy treatment, offering a clinical reference for potential ICI targets in MSS CRCs.

论文信息

作者
Yan H、Jiang L、Li Y、Wang F、Mo S、Sheng W、Huang D、Peng J
单位
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.China
文献类型
非美国政府资助研究
期刊
JMIR formative research2025 Oct 16
原文标识
PubMed 41100766 · DOI 10.2196/66960